profit from every $100 of sales.
$0$100
Nasus Pharma
$2.91-2.51% today
-61.2% in 1 year
1-year low $2.011-year high $9.15
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Nasus Pharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$5.86 million of profit last year.
SalesProfit
Nasus Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Nasus Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Nasus Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -2 | -1 | -1 | -5 | |
| -2 | -1 | -1 | -5 | |
| -2 | -1 | -2 | -6 | |
| -0.24 | -0.20 | -0.22 | -0.72 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 0 | 0 | 1 | 5 |
| Cash | 0 | 0 | 0 | 1 |
| Total debt | 2 | 2 | 2 | 0 |
| Total liabilities | 3 | 4 | 4 | 2 |
| -3 | -4 | -3 | 3 | |
| 7 | 7 | 7 | 8 | |
| – | – | – | -134.2% | |
| 61.4% | 27.7% | 47.7% | -211.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1 | -1 | -1 | -5 | |
| – | – | – | 0 | |
| -1 | -1 | -1 | -5 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 0.0×
- –
- –
- –
- –
- -4.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- –
- 0.0%
- 0.0%
- 0.0%
- –
Growth
- –
- –
- –
- –
- +0.0%
Financial health
- 0.0×
- 0.00
- 0.0%
- -37.2×
- –
- –
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 33%of 959
Bottom 21%of 888
What analysts expect
- Average price target
- $22.00
- Range
- $22.00 – $22.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
53No pass
Philip Fisher
39No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
26No pass
Questions about Nasus Pharma
Is Nasus Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nasus Pharma AI analysis
What does Nasus Pharma do?
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. It is in Biotechnology.
Does Nasus Pharma pay a dividend?
No. Nasus Pharma does not pay a dividend at the moment.
Is Nasus Pharma stock halal?
Yes. Nasus Pharma passes our halal screen: its business is permitted and its debt is 0.3% of its market value, under the 30% limit. How we check
How has Nasus Pharma stock done over the past year?
Down 61.2% over the past twelve months, to $2.91. It traded between $2.01 and $9.15 and is 68.2% below its high.
Who are Nasus Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Nasus Pharma's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.